Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Montesi, Sydney B ^a   Mathai, Susan K ^b   Brenner, Laura N ^a   Gorshkova, Irina A ^c   Berdyshev, Evgeny V ^c   Tager, Andrew M ^a   Shea, Barry S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Exhaled breath condensate; Idiopathic pulmonary fibrosis; Lysophosphatidic acid

Indexed keywords

AGED; BREATH TESTS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LYSOPHOSPHOLIPIDS; MALE;

EID: 84892875117     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-5     Document Type: Article

References (38)

1. Selman M. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy. Ann Intern Med 2001, 134:136-151. 10.7326/0003-4819-134-2-200101160-00015, 11177318.
2. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001, 345:517-525. 10.1056/NEJMra003200, 11519507.
3. Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, Egan JJ, Lambrecht BN, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C, Verbeken E, Verschakelen JA, Wells AU, Verleden GM. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2013, 41:1207-1218. 10.1183/09031936.00073012, 23100500.
4. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440. 10.1164/rccm.201006-0894CI, 20935110.
5. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824. 10.1164/rccm.2009-040GL, 21471066.
6. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010, 4:367-388. 10.1177/1753465810379801, 20952439.
7. Shea BS, Tager AM. Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc 2012, 9:102-110. 10.1513/pats.201201-005AW, 22802282.
8. Baker DL, Umstot ES, Desiderio DM, Tigyi GJ. Quantitative analysis of lysophosphatidic acid in human blood fractions. Ann N Y Acad Sci 2000, 905:267-269.
9. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJO, Saulnier-Blache J-S, Mummery CL, Moolenaar WH, Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006, 26:5015-5022. 10.1128/MCB.02419-05, 1489177, 16782887.
10. Albers HMHG, Dong A, van Meeteren LA, Egan DA, Sunkara M, van Tilburg EW, Schuurman K, van Tellingen O, Morris AJ, Smyth SS, Moolenaar WH, Ovaa H. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A 2010, 107:7257-7262. 10.1073/pnas.1001529107, 2867685, 20360563.
11. Moolenaar WH, van Meeteren LA, Giepmans BNG. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004, 26:870-881. 10.1002/bies.20081, 15273989.
12. Davenport AP, Alexander SPH, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 2013, 65:967-986. 10.1124/pr.112.007179, 3698937, 23686350.
13. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND, Hart WK, Pardo A, Blackwell TS, Xu Y, Chun J, Luster AD. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008, 14:45-54. 10.1038/nm1685, 18066075.
14. Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011, 63:1405-1415. 10.1002/art.30262, 3086986, 21305523.
15. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, Tejima K, Nishikawa T, Arai M, Yanase M, Aoki J, Arai H, Omata M, Fujiwara K, Yatomi Y. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 2007, 81:1009-1015. 10.1016/j.lfs.2007.08.013, 17850827.
16. Sakai N, Chun J, Duffield JS, Wada T, Luster AD, Tager AM. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J 2013, 27:1830-1846. 10.1096/fj.12-219378, 23322166.
17. Pradère JP, Klein J, Gres S, Guigné C, Neau E, Valet P, Calise D, Chun J, Bascands J-L, Saulnier-Blache J-S, Schanstra JP. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007, 18:3110-3118. 10.1681/ASN.2007020196, 18003779.
18. Funke M, Zhao Z, Xu Y, Chun J, Tager AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 2012, 46:355-364. 10.1165/rcmb.2010-0155OC, 3326436, 22021336.
19. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC, Fagan P, Baccei CS, Santini AM, Hutchinson JH, Seiders TJ, Parr TA, Prasit P, Evans JF, Lorrain DS. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 2010, 160:1699-1713. 10.1111/j.1476-5381.2010.00828.x, 2936842, 20649573.
20. Huang LS, Fu P, Patel P, Harijith A, Sun T, Zhao Y, Garcia JGN, Chun J, Natarajan V. Lysophosphatidic Acid Receptor 2 Deficiency Confers Protection Against Bleomycin-Induced Lung Injury and Fibrosis in Mice. Am J Respir Cell Mol Biol 2013, 49:912-922. 10.1165/rcmb.2013-0070OC, 23808384.
21. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, Jenkins G. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009, 174:1264-1279. 10.2353/ajpath.2009.080160, 2671359, 19147812.
22. Kazani SS, Israel EE. Utility of exhaled breath condensates across respiratory diseases. Am J Respir Crit Care Med 2012, 185:791-792. 10.1164/rccm.201202-0212ED, 22505746.
23. Antczak A, Piotrowski W, Marczak J, Ciebiada M, Gorski P, BARNES PJ. Correlation between eicosanoids in bronchoalveolar lavage fluid and in exhaled breath condensate. Dis Markers 2011, 30:213-220. 10.1155/2011/323794, 3825235, 21734340.
24. Effros RMR, Casaburi RR, Porszasz JJ, Morales EME, Rehan VV. Exhaled breath condensates: analyzing the expiratory plume. Am J Respir Crit Care Med 2012, 185:803-804. 10.1164/rccm.201109-1702ED, 3360569, 22505753.
25. Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G, Wechsler ME, Levy BD, Israel E. Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol 2013, 132:547-553. 10.1016/j.jaci.2013.01.058, 23608729.
26. Antczak A, Ciebiada M, Pietras T, Piotrowski WJ, Kurmanowska Z, Górski P. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci 2012, 8:277-285. 3361040, 22662001.
27. Chow SS, Thomas PSP, Malouf MM, Yates DHD. Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis. J Breath Res 2012, 6:016004-016014. 10.1088/1752-7155/6/1/016004, 22233623.
28. Psathakis KK, Mermigkis DD, Papatheodorou GG, Loukides SS, Panagou PP, Polychronopoulos VV, Siafakas NMN, Bouros DD. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur J Clin Invest 2006, 36:362-367. 10.1111/j.1365-2362.2006.01636.x, 16634841.
29. Horváth I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJC, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jöbsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen ELJ, Rubinstein I, Silkoff P, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005, 26:523-548. 10.1183/09031936.05.00029705, 16135737.
30. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993, 291(Pt 3):677-680. 1132420, 8489494.
31. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917. 10.1139/o59-099, 13671378.
32. Berdyshev EV, Gorshkova IA, Usatyuk P, Zhao Y, Saatian B, Hubbard W, Natarajan V. De novo biosynthesis of dihydrosphingosine-1-phosphate by sphingosine kinase 1 in mammalian cells. Cell Signal 2006, 18:1779-1792. 10.1016/j.cellsig.2006.01.018, 16529909.
33. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett 2000, 478:159-165. 10.1016/S0014-5793(00)01827-5, 10922489.
34. Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010, 161:241-270. 10.1111/j.1476-5381.2010.00815.x, 2989581,2989581, 20735414.
35. Tokumura A, Sinomiya J, Kishimoto S, Tanaka T, Kogure K, Sugiura T, Satouchi K, Waku K, Fukuzawa K. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Biochem J 2002, 365:617-628. 1222725, 11982483.
36. Berry KAZ, Li B, Reynolds SD, Barkley RM, Gijón MA, Hankin JA, Henson PM, Murphy RC. MALDI imaging MS of phospholipids in the mouse lung. J Lipid Res 2011, 52:1551-1560. 10.1194/jlr.M015750, 3137021, 21508254.
37. Georas SN, Berdyshev E, Hubbard W, Gorshkova IA, Usatyuk PV, Saatian B, Myers AC, Williams MA, Xiao HQ, Liu M, Natarajan V. Lysophosphatidic acid is detectable in human bronchoalveolar lavage fluids at baseline and increased after segmental allergen challenge. Clin Exp Allergy 2007, 37:311-322. 10.1111/j.1365-2222.2006.02626.x, 17359381.
38. Park GY, Lee YG, Berdyshev E, Nyenhuis S, Du J, Fu P, Gorshkova IA, Li Y, Chung S, Karpurapu M, Deng J, Ranjan R, Xiao L, Jaffe HA, Corbridge SJ, Kelly EAB, Jarjour NN, Chun J, Prestwich GD, Kaffe E, Ninou I, Aidinis V, Morris AJ, Smyth SS, Ackerman SJ, Natarajan V, Christman JW. Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med 2013, 188:928-940. 10.1164/rccm.201306-1014OC, 24050723.